ArticleThe Lancet regional health. Europe2026
Estimating incidence rates of primary infection and reinfection with hepatitis C virus among people who inject drugs in Scotland: a model-based analysis of repeated cross-sectional survey data.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Antiviral Therapy Scale-Up Among People Who Inject Drugs in Scotland: Regional Evidence of Hepatitis C Virus Elimination.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reducing the incidence of hepatitis C virus (HCV) infection is a World Health Organization (WHO) elimination goal, but approaches to estimate this from population-level survey data are lacking. We modelled HCV incidence among people who inject drugs (PWID) surveyed over time, to provide evidence on whether Scotland has reached the WHO elimination target of ≤2 per 100 person-years in this population. Methods: A statistical model was fitted using HCV infection data from five sweeps (2013-14, 2015-16, 2017-18, 2019-20, and 2022-23) of a national bio-behavioural survey, involving 11,651 PWID recruited at sites providing injecting equipment. Per-sweep incidence rates of primary chronic HCV infection, reinfection, and combined primary and reinfection ('total infection') were inferred within a Bayesian framework. Incidence rates relate to the number of new infections per 100 person-years for the population at risk of (primary, reinfection and total) infection. Findings: In 2022-23, the model-estimated total, re-infection and primary infection incidence rates were 3.4 per 100 person-years (95% credible interval (CrI):2.6-4.3), 1.9 (1.3-2.6), and 4.1 (3.0-5.4), respectively. For total new infections, the model-estimated incidence rate decreased by 51% from 7.0 per 100 person-years in 2015-16 to 3.4 in 2022-23 (relating to an absolute decrease of 3.6 per 100 person-years; 95% CrI: 2.0-5.3). Between 2015-16 and 2022-23, model-estimated re-infection and primary infection incidence rates decreased by 78% and 40%, respectively. Interpretation: Over a period when direct-acting antiviral therapy was scaled-up in Scotland, major reductions in the incidence of primary infection, reinfection, and total HCV infection were evident, indicating that the WHO target is within reach, for a relatively high-risk population of PWID. Funding: Public Health Scotland (for NESI); NIHR HPRU in Behavioural Science and Evaluation; NIHR Programme Grants for Applied Research programme (reference number RP-PG-0616-20008).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.